Opgenra

RSS

Withdrawn

This medicine's authorisation has been withdrawn

eptotermin alfa
MedicineHumanWithdrawn

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 1 July 2016, the European Commission withdrew the marketing authorisation for Opgenra (eptotermin alfa) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Olympus Biotech International Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Opgenra was granted marketing authorisation in the EU on 19 February 2009 for treatment of spondylolisthesis. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2013. 

The European Public Assessment Report (EPAR) for Opgenra is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (709.65 kB - PDF)

Bekijk

español (ES) (582.84 kB - PDF)

Bekijk

čeština (CS) (592.56 kB - PDF)

Bekijk

dansk (DA) (583.5 kB - PDF)

Bekijk

Deutsch (DE) (590.01 kB - PDF)

Bekijk

eesti (ET) (520.97 kB - PDF)

Bekijk

ελληνικά (EL) (661.16 kB - PDF)

Bekijk

français (FR) (524.93 kB - PDF)

Bekijk

italiano (IT) (525.11 kB - PDF)

Bekijk

latviešu (LV) (658.97 kB - PDF)

Bekijk

lietuvių (LT) (552.27 kB - PDF)

Bekijk

magyar (HU) (583.85 kB - PDF)

Bekijk

Malti (MT) (672.79 kB - PDF)

Bekijk

Nederlands (NL) (541.61 kB - PDF)

Bekijk

polski (PL) (667.42 kB - PDF)

Bekijk

português (PT) (537.23 kB - PDF)

Bekijk

română (RO) (553.82 kB - PDF)

Bekijk

slovenčina (SK) (1.03 MB - PDF)

Bekijk

slovenščina (SL) (583.13 kB - PDF)

Bekijk

suomi (FI) (522.19 kB - PDF)

Bekijk

svenska (SV) (521.89 kB - PDF)

Bekijk

Product information

български (BG) (1.87 MB - PDF)

Bekijk

español (ES) (1.2 MB - PDF)

Bekijk

čeština (CS) (1.62 MB - PDF)

Bekijk

dansk (DA) (1.2 MB - PDF)

Bekijk

Deutsch (DE) (1.24 MB - PDF)

Bekijk

eesti (ET) (1.18 MB - PDF)

Bekijk

ελληνικά (EL) (1.92 MB - PDF)

Bekijk

français (FR) (1.22 MB - PDF)

Bekijk

hrvatski (HR) (1.24 MB - PDF)

Bekijk

italiano (IT) (1.21 MB - PDF)

Bekijk

latviešu (LV) (1.62 MB - PDF)

Bekijk

lietuvių (LT) (1.27 MB - PDF)

Bekijk

magyar (HU) (1.64 MB - PDF)

Bekijk

Malti (MT) (1.65 MB - PDF)

Bekijk

Nederlands (NL) (1.24 MB - PDF)

Bekijk

polski (PL) (1.63 MB - PDF)

Bekijk

português (PT) (1.19 MB - PDF)

Bekijk

română (RO) (1.28 MB - PDF)

Bekijk

slovenčina (SK) (2.2 MB - PDF)

Bekijk

slovenščina (SL) (1.57 MB - PDF)

Bekijk

suomi (FI) (1.2 MB - PDF)

Bekijk

svenska (SV) (1.19 MB - PDF)

Bekijk

Íslenska (IS) (1.17 MB - PDF)

Bekijk

norsk (NO) (1.19 MB - PDF)

Bekijk
Latest procedure affecting product information:IG/0473/G
01/07/2016
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (552.36 kB - PDF)

Bekijk

español (ES) (464.84 kB - PDF)

Bekijk

čeština (CS) (544.1 kB - PDF)

Bekijk

dansk (DA) (467.77 kB - PDF)

Bekijk

Deutsch (DE) (464.93 kB - PDF)

Bekijk

eesti (ET) (464.72 kB - PDF)

Bekijk

ελληνικά (EL) (548.15 kB - PDF)

Bekijk

français (FR) (464.43 kB - PDF)

Bekijk

italiano (IT) (464.27 kB - PDF)

Bekijk

latviešu (LV) (543.63 kB - PDF)

Bekijk

lietuvių (LT) (529.55 kB - PDF)

Bekijk

magyar (HU) (507.79 kB - PDF)

Bekijk

Malti (MT) (544.35 kB - PDF)

Bekijk

Nederlands (NL) (464.48 kB - PDF)

Bekijk

polski (PL) (547.05 kB - PDF)

Bekijk

português (PT) (464.65 kB - PDF)

Bekijk

română (RO) (527.4 kB - PDF)

Bekijk

slovenčina (SK) (994.79 kB - PDF)

Bekijk

slovenščina (SL) (476.21 kB - PDF)

Bekijk

suomi (FI) (464.46 kB - PDF)

Bekijk

svenska (SV) (481.49 kB - PDF)

Bekijk

norsk (NO) (622.87 kB - PDF)

Bekijk

български (BG) (818.76 kB - PDF)

Bekijk

español (ES) (499.15 kB - PDF)

Bekijk

čeština (CS) (782.65 kB - PDF)

Bekijk

dansk (DA) (678.87 kB - PDF)

Bekijk

Deutsch (DE) (624.42 kB - PDF)

Bekijk

eesti (ET) (609.17 kB - PDF)

Bekijk

ελληνικά (EL) (817.11 kB - PDF)

Bekijk

français (FR) (700.32 kB - PDF)

Bekijk

italiano (IT) (693.06 kB - PDF)

Bekijk

latviešu (LV) (765.09 kB - PDF)

Bekijk

lietuvių (LT) (722.78 kB - PDF)

Bekijk

magyar (HU) (712.62 kB - PDF)

Bekijk

Malti (MT) (761.19 kB - PDF)

Bekijk

Nederlands (NL) (627.42 kB - PDF)

Bekijk

polski (PL) (840.43 kB - PDF)

Bekijk

português (PT) (699.86 kB - PDF)

Bekijk

română (RO) (732.14 kB - PDF)

Bekijk

slovenčina (SK) (142.87 kB - PDF)

Bekijk

slovenščina (SL) (605.13 kB - PDF)

Bekijk

suomi (FI) (604.16 kB - PDF)

Bekijk

svenska (SV) (481.49 kB - PDF)

Bekijk

norsk (NO) (622.87 kB - PDF)

Bekijk

Product details

Name of medicine
Opgenra
Active substance
eptotermin alfa
International non-proprietary name (INN) or common name
eptotermin alfa
Therapeutic area (MeSH)
Spondylolisthesis
Anatomical therapeutic chemical (ATC) code
M05BC02

Pharmacotherapeutic group

Drugs for treatment of bone diseases

Therapeutic indication

Opgenra is indicated for posterolateral lumbar spinal fusion in adult patients with spondylolisthesis where autograft has failed or is contra-indicated.

Authorisation details

EMA product number
EMEA/H/C/000819
Marketing authorisation holder
Olympus Biotech International Limited

Block 2
International Science Centre
National Technology Park
Castletroy
Limerick
Ireland

Marketing authorisation issued
19/02/2009
Withdrawal of marketing authorisation
01/07/2016
Revision
9

Assessment history

This page was last updated on

Share this page